Prior Authorization DRUG Guidelines

VARUBI (Rolapitant)

Effective Date: 4/23/19

Date Developed: 2/26/19 by R. Sterling

Date Approved by P&T Committee: 4/23/19

Last Approval Date: 2/18/20

Varubi is used alone or in combination with other agents to prevent delayed nausea and vomiting associated with emetogenic chemotherapy by selectively and competitively inhibiting the substance P/neurokinin 1 (NK1) receptor.

Pre-Authorization Criteria:

VCHCP will approve Varubi as an oral agent when used at home prior to chemotherapy on day 1 only. VCHCP will also approve oral use of Varubi two hours prior to the administration of moderately emetogenic chemotherapy, such as cisplatin/anthracycline/cyclophosphamide. VCHCP will discourage the use of the IV form due to reports of serious and potentially life-threatening anaphylactic reactions. Prior to use of either form of Varubi, VCHCP will require documentation of a significant failure of alternative medications (see below) and/or a compelling reason submitted by the requesting physician to use Varubi as a primary therapeutic agent.

Dose: 180 mg as a single dose (2 of 90mg tablets). The Drug Quantity limit is 2 tablets.

How supplied: Tablets: 90 mg; Emulsion for IV use: 166.5 mg/92.5 ml

Caution: The mean half-life of Varubi is approximately seven days. It is not to be used at less than two-week intervals. Life-threatening anaphylactic reactions have been reported when used intravenously. Varubi is a moderate CYP2D6 inhibitor (avoid in combination with thioridazine and pimozide).

Other therapeutics agents: ondansetron, metoclopramide; dexamethasone; olanzepine; promethazine; prochlorperazine; benzodiazipines; alternative medicines (cannabinoids e.g. dronabinol/Marinol; ginger; acupuncture)

==================================================================================

Varubi is to be prescribed to be used 2 hours prior to administration of moderately emetogenic chemotherapy, which includes cisplatin/anthracycline/cyclophosphamide. The oral form of Varubi is to be prescribed, to be taken at home prior to chemotherapy on day 1 only. The dosing is 180 mg as a single dose (2 of 90mg tablets). The Drug Quantity Limit for po Varubi is 2.
The IV form of Varubi is to be prescribed only if the oral drug cannot be given or is not tolerated. This is also to be given 2 hours prior to chemotherapy on day 1 only, infused over 30 minutes. VCHCP requires that Varubi be prescribed by a physician specializing in oncology.

**Dosing Forms:**
Tablet: 90 mg
Emulsion, IV: 166.5mg/92.5ml

**Warning:** Do not use Varubi at less than 2-week intervals.

**Revision History:**
Date Approved by P&T Committee: 4/23/19; QAC: 05/28/19
Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/18/20

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2/26/19</td>
<td>No</td>
<td>Robert Sterling, MD</td>
<td>Created</td>
</tr>
<tr>
<td>2/18/20</td>
<td>No</td>
<td>Howard Taekman, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>